These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

385 related articles for article (PubMed ID: 35656777)

  • 21. Disease volume and risk subgroup analyses for darolutamide plus androgen-deprivation therapy and docetaxel in the phase III ARASENS: should triplet therapy become standard of care in certain metastatic hormone-sensitive prostate cancer patients?
    Hoeh B; Chun FKH; Mandel P
    Chin Clin Oncol; 2024 Feb; 13(1):14. PubMed ID: 37817509
    [No Abstract]   [Full Text] [Related]  

  • 22. Darolutamide and health-related quality of life in patients with non-metastatic castration-resistant prostate cancer: An analysis of the phase III ARAMIS trial.
    Smith MR; Shore N; Tammela TL; Ulys A; Vjaters E; Polyakov S; Jievaltas M; Luz M; Alekseev B; Kuss I; Le Berre MA; Mohamed AF; Odom D; Bartsch J; Snapir A; Sarapohja T; Fizazi K
    Eur J Cancer; 2021 Sep; 154():138-146. PubMed ID: 34273811
    [TBL] [Abstract][Full Text] [Related]  

  • 23. SYSTEMIC TRIPLE THERAPY IN METASTATIC HORMONE SENSITIVE PROSTATE CANCER (MHSPC).
    Omrčen T
    Acta Clin Croat; 2022 Oct; 61(Suppl 3):81-85. PubMed ID: 36938560
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Apalutamide Compared with Darolutamide for the Treatment of Non-metastatic Castration-Resistant Prostate Cancer: Efficacy and Tolerability in a Matching-Adjusted Indirect Comparison.
    Chowdhury S; Oudard S; Uemura H; Joniau S; Dearden L; Capone C; Van Sanden S; Diels J; Hadaschik BA
    Adv Ther; 2022 Jan; 39(1):518-531. PubMed ID: 34797506
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Qualitative and Quantitative Assessment of Patient and Carer Experience of Chemotherapy (Docetaxel) in Combination with Androgen Deprivation Therapy (ADT) for the Treatment of Metastatic Hormone-Sensitive Prostate Cancer (mHSPC).
    Ito T; Grant L; Duckham BR; Ribbands AJ; Gater A
    Adv Ther; 2018 Dec; 35(12):2186-2200. PubMed ID: 30415297
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Chemotherapy and advanced androgen blockage, alone or combined, for metastatic hormone-sensitive prostate cancer a systematic review and meta-analysis.
    Fallara G; Robesti D; Nocera L; Raggi D; Marandino L; Belladelli F; Montorsi F; Malavaud B; Ploussard G; Necchi A; Martini A
    Cancer Treat Rev; 2022 Nov; 110():102441. PubMed ID: 35939976
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Health-related quality of life in patients with metastatic hormone-sensitive prostate cancer treated with androgen receptor signaling inhibitors: the role of combination treatment therapy.
    Afferi L; Longoni M; Moschini M; Gandaglia G; Morgans AK; Cathomas R; Mattei A; Breda A; Scarpa RM; Papalia R; de Nunzio C; Esperto F
    Prostate Cancer Prostatic Dis; 2024 Jun; 27(2):173-182. PubMed ID: 37055663
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Impact of disease volume on survival efficacy of triplet therapy for metastatic hormone-sensitive prostate cancer: a systematic review, meta-analysis, and network meta-analysis.
    Matsukawa A; Rajwa P; Kawada T; Bekku K; Laukhtina E; Klemm J; Pradere B; Mori K; Karakiewicz PI; Kimura T; Chlosta P; Shariat SF; Yanagisawa T
    Int J Clin Oncol; 2024 Jun; 29(6):716-725. PubMed ID: 38582807
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Addition of New Androgen Receptor Pathway Inhibitors to Docetaxel and Androgen Deprivation Therapy in Metastatic Hormone-Sensitive Prostate Cancer: A Systematic Review and Metanalysis.
    Fiorica F; Buttigliero C; Grigolato D; Muraro M; Turco F; Munoz F; Tucci M
    Curr Oncol; 2022 Dec; 29(12):9511-9524. PubMed ID: 36547161
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Based on ARASENS trial: efficacy and safety of darolutamide as an emerging option of endocrinotherapy for metastatic hormone-sensitive prostate cancer-an updated systematic review and network meta-analysis.
    Dou M; Liang H; Liu Y; Zhang Q; Li R; Chen S; Shi B
    J Cancer Res Clin Oncol; 2023 Aug; 149(10):7017-7027. PubMed ID: 36856851
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Addition of Docetaxel to Androgen Receptor Axis-targeted Therapy and Androgen Deprivation Therapy in Metastatic Hormone-sensitive Prostate Cancer: A Network Meta-analysis.
    Roy S; Sayyid R; Saad F; Sun Y; Lajkosz K; Ong M; Klaassen Z; Malone S; Spratt DE; Wallis CJD; Morgan SC
    Eur Urol Oncol; 2022 Oct; 5(5):494-502. PubMed ID: 35811293
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cost-Utility Analysis of Darolutamide Combined with Androgen Deprivation Therapy for Patients with High-Risk Non-Metastatic Castration-Resistant Prostate Cancer in China.
    Ming J; Wu Y; Han R; Xu X; Waldeck R; Hu S
    Adv Ther; 2023 Mar; 40(3):1087-1103. PubMed ID: 36630046
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evaluation of Clinically Relevant Drug-Drug Interactions and Population Pharmacokinetics of Darolutamide in Patients with Nonmetastatic Castration-Resistant Prostate Cancer: Results of Pre-Specified and Post Hoc Analyses of the Phase III ARAMIS Trial.
    Shore N; Zurth C; Fricke R; Gieschen H; Graudenz K; Koskinen M; Ploeger B; Moss J; Prien O; Borghesi G; Petrenciuc O; Tammela TL; Kuss I; Verholen F; Smith MR; Fizazi K
    Target Oncol; 2019 Oct; 14(5):527-539. PubMed ID: 31571095
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Current status and future perspectives of the managements of metastatic hormone-sensitive prostate cancer.
    Matsumura N; Fujita K; Nishimoto M; Minami T; Tahara H; Yoshimura K; Uemura H
    World J Urol; 2023 Aug; 41(8):2063-2068. PubMed ID: 36040500
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Combination of docetaxel versus nonsteroidal antiandrogen with androgen deprivation therapy for high-volume metastatic hormone-sensitive prostate cancer: a propensity score-matched analysis.
    Yanagisawa T; Kimura T; Hata K; Narita S; Hatakeyama S; Mori K; Sano T; Otsuka T; Iwamoto Y; Enei Y; Nakazono M; Sakanaka K; Iwatani K; Matsukawa A; Atsuta M; Nishikawa H; Tsuzuki S; Miki J; Habuchi T; Ohyama C; Shariat SF; Egawa S
    World J Urol; 2023 Aug; 41(8):2051-2062. PubMed ID: 35596809
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The Health Economics of Metastatic Hormone-Sensitive and Non-Metastatic Castration-Resistant Prostate Cancer-A Systematic Literature Review with Application to the Canadian Context.
    Yanev I; Gatete J; Aprikian AG; Guertin JR; Dragomir A
    Curr Oncol; 2022 May; 29(5):3393-3424. PubMed ID: 35621665
    [No Abstract]   [Full Text] [Related]  

  • 37. Efficacy and Safety of Darolutamide in Patients with Nonmetastatic Castration-resistant Prostate Cancer Stratified by Prostate-specific Antigen Doubling Time: Planned Subgroup Analysis of the Phase 3 ARAMIS Trial.
    Bögemann M; Shore ND; Smith MR; Tammela TLJ; Ulys A; Vjaters E; Polyakov S; Jievaltas M; Luz M; Alekseev B; Lebret T; Schostak M; Verholen F; Le Berre MA; Srinivasan S; Ortiz J; Mohamed AF; Sarapohja T; Fizazi K
    Eur Urol; 2023 Mar; 83(3):212-221. PubMed ID: 36089529
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Anticancer Activity and Tolerance of Treatments Received Beyond Progression in Men Treated Upfront with Androgen Deprivation Therapy With or Without Docetaxel for Metastatic Castration-naïve Prostate Cancer in the GETUG-AFU 15 Phase 3 Trial.
    Lavaud P; Gravis G; Foulon S; Joly F; Oudard S; Priou F; Latorzeff I; Mourey L; Soulié M; Delva R; Krakowski I; Laguerre B; Théodore C; Ferrero JM; Beuzeboc P; Habibian M; Rolland F; Deplanque G; Pouessel D; Zanetta S; Berdah JF; Dauba J; Baciuchka M; Platini C; Linassier C; Tubiana-Mathieu N; Machiels JP; Kouri CE; Ravaud A; Suc E; Eymard JC; Hasbini A; Bousquet G; Culine S; Boher JM; Tergemina-Clain G; Legoupil C; Fizazi K
    Eur Urol; 2018 May; 73(5):696-703. PubMed ID: 29074061
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Use of docetaxel plus androgen deprivation therapy for metastatic hormone-sensitive prostate cancer in Korean patients: A retrospective study.
    Kwon WA; Joung JY; Lee JE; Choi SY; Kim SH; Seo HK; Lee KH; Kim CS
    Investig Clin Urol; 2019 May; 60(3):195-201. PubMed ID: 31098427
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Real-World Evidence of Triplet Therapy in Metastatic Hormone-Sensitive Prostate Cancer: An Austrian Multicenter Study.
    Kafka M; Giannini G; Artamonova N; Neuwirt H; Ofner H; Kramer G; Bauernhofer T; Luger F; Höfner T; Loidl W; Griessner H; Lusuardi L; Bergmaier A; Berger A; Winder T; Weiss S; Bauinger S; Krause S; Drerup M; Heinrich E; Schneider M; Madersbacher S; Vallet S; Stoiber F; Laimer S; Hruby S; Schachtner G; Nagele U; Lenart S; Ponholzer A; Pfuner J; Wiesinger C; Kamhuber C; Müldür E; Bektic J; Horninger W; Heidegger I
    Clin Genitourin Cancer; 2024 Apr; 22(2):458-466.e1. PubMed ID: 38267304
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.